[HTML][HTML] Genetics and epigenetics in asthma

P Ntontsi, A Photiades, E Zervas, G Xanthou… - International Journal of …, 2021 - mdpi.com
Asthma is one of the most common respiratory disease that affects both children and adults
worldwide, with diverse phenotypes and underlying pathogenetic mechanisms poorly …

[HTML][HTML] Advantages and limitations of the neonatal immune system

GP Tsafaras, P Ntontsi, G Xanthou - Frontiers in pediatrics, 2020 - frontiersin.org
During early post-natal life, neonates must adjust to the transition from the sheltered intra-uterine
environment to the microbe-laden external world, wherein they encounter a …

[HTML][HTML] Eosinophilic asthma, phenotypes-endotypes and current biomarkers of choice

…, I Tsiouprou, A Apostolopoulos, P Ntontsi… - Journal of Personalized …, 2022 - mdpi.com
Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic
agents have been developed towards a personalized approach to asthma management. This …

Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study

…, E Papathanasiou, P Ntontsi… - Postgraduate …, 2017 - Taylor & Francis
Objectives: Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody,
used for the treatment of severe refractory allergic asthma. However, not all patients with IgE …

[HTML][HTML] Paucigranulocytic asthma: potential pathogenetic mechanisms, clinical features and therapeutic management

AI Papaioannou, E Fouka, P Ntontsi… - Journal of Personalized …, 2022 - mdpi.com
Asthma is a heterogeneous disease usually characterized by chronic airway inflammation,
in which several phenotypes have been described, related to the age of onset, symptoms, …

Targeted anti-IL-13 therapies in asthma: current data and future perspectives

P Ntontsi, E Papathanassiou, S Loukides… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: The identification of patients with severe asthma who will benefit from a
personalized management approach remains an unmet need. Interleukin-13 (IL-13) is a cytokine …

Severe asthma: what is new in the new millennium

P Ntontsi, K Samitas, E Zervas… - Current Opinion in Allergy …, 2020 - journals.lww.com
Novel anti-IL5 agents have changed the management of T2-high asthma resulting in
improved disease control, QoL and lung function and importantly, fewer exacerbations. …

Biomarkers guided treatment strategies in adult patients with asthma: ready for the clinical field?

Z Tsilogianni, P Ntontsi, AI Papaioannou… - Archivum Immunologiae …, 2017 - Springer
Asthma is a chronic inflammatory airways disorder mainly characterized by heterogeneity.
In the more severe forms, a discordance often exists between symptoms and inflammation. …

Experimental and investigational phosphodiesterase inhibitors in development for asthma

P Ntontsi, A Detta, P Bakakos, S Loukides… - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: Severe, inadequately-controlled asthma remains a clinical challenge. For this
reason, clinical trials and preclinical experimental studies on novel agents as an add-on …

Exhaled breath temperature in optimally treated asthmatics: severity and underlying mechanisms

P Ntontsi, P Bakakos, E Papathanasiou… - Journal of Breath …, 2018 - iopscience.iop.org
Introduction. Increased vascularity may lead to loss of heat in the airways and may modulate
exhaled breath temperature (EBT). Increased EBT has been associated with uncontrolled …